Status:
COMPLETED
An INternational Frontline Ovarian Cancer Real World Management Study
Lead Sponsor:
AstraZeneca
Conditions:
Ovarian Neoplasms
Eligibility:
FEMALE
Brief Summary
The current study aims to analyze the existing secondary databases from Korea (Sungkyunkwan University, Samsung Medical Center, Seoul), Taiwan (National Taiwan University, Chang-Gung Medical Foundatio...
Detailed Description
Ovarian cancer is the eighth most commonly diagnosed cancer (295,414 cases reported in 2018) and the seventh leading cause of cancer-associated mortality (184,799 deaths reported in 2018) in women, wo...
Eligibility Criteria
Inclusion
- Female subjects above the age of 18
- Patients with a confirmed diagnosis of advanced-stage (FIGO III/IV) epithelial (Serous \[high or low grade\], mucinous, endometrioid, clear cell, mixed, and others) ovarian cancer between the period Jan 2014 and Dec 2018, provided at least 12 months data is available (not mandatory to be ovarian cancer related) as a proxy of healthcare use prior to the diagnosis of advanced-stage epithelial ovarian cancer
Exclusion
- Patients being included in interventional clinical trials with PARPi for the treatment of advanced-stage high-grade epithelial ovarian cancer treatment during the study period
- Patients with early stage disease (FIGO Stage I, IIA, IIB, or IIC)
- Other malignancies within the past five years, except adequately treated non-melanoma skin cancer; curatively treated in situ cancer of the cervix; ductal carcinoma in situ; stage 1, grade 1 endometrial carcinoma; or other solid tumors including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥5 years. Patients with a history of localized breast cancer may have been eligible, provided they completed their adjuvant chemotherapy more than three years prior to registration, and remained free of recurrent or metastatic disease
Key Trial Info
Start Date :
June 27 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 10 2020
Estimated Enrollment :
989 Patients enrolled
Trial Details
Trial ID
NCT04460768
Start Date
June 27 2020
End Date
November 10 2020
Last Update
September 27 2021
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Melbourne, Victoria, Australia, D0817R00028
2
Research Site
Seoul, South Korea, D0817R00028
3
Research Site
New Taipei City, Taiwan, D0817R00028
4
Research Site
Taipei, Taiwan, D0817R00028